For the Inventor, By the Inventor

Enter assignee name

Asahi Kasei Pharma Corporation

USPTO Granted Patents = 84

% Expired Patents = 53.6

CIPO Patents = 4

EPO Patents = 44

Trademarks = 1

Forward Citations = 240

Loading Chart...

Loading Chart...

129 inventors (with patents filed for the assignee):

Motoshi Shoda (7 out of 8 patents)

Takeshi Matsuoka (6 out of 7 patents)

Rintaro Yamada (6 out of 6 patents)

4. Minoru Seto (6 out of 11 patents)

5. Takuji Kouzuma (6 out of 6 patents)

6. Shigeyuki Imamura (5 out of 6 patents)

7. Koki Matsubara (5 out of 5 patents)

8. Shiro Miyoshi (5 out of 12 patents)

9. Shinichi Sakasegawa (4 out of 5 patents)

10. Fumihide Nishio (4 out of 4 patents)

11. Kazuhisa Tsuruta (4 out of 4 patents)

12. Yoshikazu Aoki (4 out of 5 patents)

13. Yutaka Osawa (4 out of 5 patents)

14. Inder Kaul (4 out of 4 patents)

15. Hiroshi Kuriyama (4 out of 6 patents)

Core Competencies:

Pyrimidine Compound

Macrocyclic Compound

Sepsis Treatment

P2X7 Receptor Antagonists

Osteoporosis Prevention

Thrombomodulin

Sulfonamide Compound

Indazole Derivatives

Peripheral Neuropathy

Fasudil

Phenylpropionic Acid

Heterocyclic Compounds

84 patents: Sort by Forward Citations

1. 12590090 - Pyrimidine-and nitrogen-containing bicyclic compound (2026-03-31),

2. 12577258 - Macrocyclic compound (2026-03-17),

3. 12514910 - MEDICAMENT FOR THERAPEUTIC TREATMENT AND/OR IMPROVEMENT OF SEPSIS ACCOMPANIED BY COAGULOPATHY (2026-01-06),

4. 12295947 - Tetrahydroquinoline derivatives as P2X7 receptor antagonists (2025-05-13),

5. 11959116 - Method for producing nicotinamide mononucleotide (2024-04-16),

6. 11667630 - Nitrogen-containing 6-membered cyclic compound (2023-06-06),

7. 11541104 - Method for preventing or treating osteoporosis, characterized by administering teriparatide or salt thereof at a frequency of twice a week (2023-01-03),

8. 11497795 - Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent (2022-11-15),

9. 11439633 - Tetrahydroquinoline derivatives as P2X7 receptor antagonists (2022-09-13),

10. 11077100 - Tetrahydroquinoline derivatives as P2X7 receptor antagonists (2021-08-03),

11. 10988468 - Nitrogen-containing 6-membered cyclic compound (2021-04-27),

12. 10975411 - Method and reagent for measuring mevalonic acid, 3-hydroxymethylglutaryl coenzyme A, and coenzyme A (2021-04-13),

13. 10900063 - Measurement of Lp-PLAactivity (2021-01-26),

14. 10709767 - Agent for prophylactic and/or therapeutic treatment of peripheral neuropathic pain caused by anticancer agent (2020-07-14),

15. 10683335 - Freeze-dried preparation containing high-purity PTH and method for producing same (2020-06-16),

Company Overview

Asahi Kasei Pharma Corporation, based in Tokyo, specializes in the development and manufacturing of pharmaceutical compounds. The company focuses on innovative treatments in various therapeutic areas, including sepsis, osteoporosis, and other critical health conditions. Its research emphasizes advanced technologies such as pyrimidine and macrocyclic compounds, as well as P2X7 receptor antagonists. Asahi Kasei Pharma is committed to enhancing patient outcomes through cutting-edge pharmaceutical solutions and a strong dedication to scientific advancement.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

84 Patents

#608 in Tokyo

#1,264 in Japan

#9,061 in the World

Asahi Kasei Pharma Corporation

Forward Citations = 240

129 inventors:

Motoshi Shoda (7 out of 8 patents)

Takeshi Matsuoka (6 out of 7 patents)

Rintaro Yamada (6 out of 6 patents)

4. Minoru Seto (6 out of 11 patents)

5. Takuji Kouzuma (6 out of 6 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Asahi Kasei Pharma Corporation. Retrieved from https://idiyas.com/company/asahi-kasei-pharma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…